Table 1.
UN-SH-SY5Y | RA-SH-SY5Y | |
---|---|---|
Control | 99.9 ± 0.1 | 100.0 ± 0.0 |
6-OHDA | 62.8 ± 0.6*** | 68.6 ± 0.2*** |
+ Nec-1 20 | 72.0 ± 2.6***,# | 70.2 ± 2.0*** |
+ Nec-1 40 | 78.2 ± 5.6***, ## | 81.2 ± 3.8**, # |
+ NAC | 81.4 ± 4.7***, ### | 83.2 ± 4.0**, # |
UN- and RA-SH-SY5Y cells were pre-treated for 30 min with necrostatin-1 (Nec-1; 20 and 40 μM) followed by 24 h of treatment with 6-hydroxydopamine (6-OHDA, 0.1 and 0.2 mM for UN- and RA-SH-SY5Y cells, respectively)
An antioxidant N-acetylcysteine (NAC, 1 mM) was given to cells concomitantly with 6-OHDA. The MTT reduction assay was employed for cell viability assessment
Data were normalized to the vehicle-treated cells and are presented as the mean ± SEM from 4 separate experiments with 5 repetitions each
**P < 0.01 and ***P < 0.001 vs. vehicle-treated cells
#P < 0.05, ##P < 0.01, and ##P < 0.001 vs. 6-OHDA-treated cells